Burg Simpson is not currently pursuing new Vioxx® cases.
Vioxx® (generic name: rofecoxib) is a is a Cox-2 inhibitor in the same drug class as Celebrex and Bextra. The FDA approved Vioxx in May 1999 following various trials and tests. Vioxx® was marketed based upon the claim that it could provide the same effects of a non-steroidal anti-inflammatory drug NSAID) without causing the gastric problems that commonly came with traditional NSAIDs. Then, in September 2004, continued testing indicated that Vioxx® reduced the risk of stomach problems in patients but significantly increased the risk of heart attacks and strokes. On September 30, 2004 Merck announced the worldwide withdrawal of Vioxx from the market. Contrary to earlier reports that increased heart risks appeared after more than 18 months’ worth of use, the evidence now shows that heart risks could occur after as few as three months of Vioxx use.
A number of Vioxx® cases have been tried. In a few cases, the plaintiffs have received large verdicts, but in a larger number of trials Merck has obtained a defense verdict. In November of 2007, Merck and the Plaintiffs’ Steering Committee announced a $4.85 Billion dollar settlement.
Michael S. Burg was appointed to the Vioxx MDL State Liaison Committee, which coordinates state and federal Vioxx® litigation, by the Hon. Eldon Fallon.